Enanta Pharmaceuticals (ENTA) to Release Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is projected to post its Q4 2025 results before the market opens on Monday, December 1st. Analysts expect Enanta Pharmaceuticals to post earnings of ($1.13) per share and revenue of $15.9710 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earningreport for the latest details on the call scheduled for Monday, November 17, 2025 at 4:00 PM ET.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The business had revenue of $15.13 million for the quarter, compared to analyst estimates of $15.60 million. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $14.13 on Friday. The company has a market cap of $301.96 million, a price-to-earnings ratio of -3.27 and a beta of 0.88. The stock has a fifty day moving average price of $11.24 and a two-hundred day moving average price of $8.74. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $15.34.

Analyst Upgrades and Downgrades

ENTA has been the subject of a number of research analyst reports. Westpark Capital lifted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Evercore ISI reduced their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JMP Securities upped their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ENTA. Quarry LP acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter worth $81,000. Algert Global LLC acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth about $133,000. Harvest Investment Services LLC acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth about $146,000. Public Employees Retirement System of Ohio increased its stake in shares of Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $186,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.